This is an example of "dare to

13
1
Favorite

Michane
2025-02-28

This is an example of "dare to dream" ..

The hope is still alive, as long as they don't give up for all the investors out there including myself. [Observation]

It is a long journey - along the way giving myself pats for the good play $NVAX 20250228 7.0 PUT$

Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines

Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines Feb 27 (Reuters) - Novavax's NVAX.O fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative

Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines

# Winning Trades

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

Top
Latest

Tiger_CashBoostAccount
·2025-03-01
Congratulations on your succeed trades. Your investment acumen is really showing. Keep leveraging your knowledge to find those hidden gems in the market. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🎉🤓
Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here.
Other helpful links:
Reply
Like
Report

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":408177892638840,"tweetId":"408177892638840","gmtCreate":1740673356619,"gmtModify":1740723039117,"author":{"id":4091891386414570,"idStr":"4091891386414570","authorId":4091891386414570,"authorIdStr":"4091891386414570","name":"Michane","avatar":"https://static.tigerbbs.com/e34d5ed60a80aa56ff9a8771c943602c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"hat":"https://static.tigerbbs.com/6444b4970948c1077534c593eccd6d16","crmLevel":12,"crmLevelSwitch":1,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":3188,"starInvestorFlag":false},"themes":[{"themeId":"7516f9ef7e8042739b8597466da26fe7","categoryId":"7cf744760f454845a1870a05ea4e151d","name":"Winning Trades","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":7516f9ef7e8042739b8597466da26fe7}&rnconfig={\"headerBarHidden\": true}","description":"Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.","image":"https://community-static.tradeup.com/news/14c89d9656aedb9a4698e7996c575947"}],"images":[{"img":"https://community-static.tradeup.com/news/463da2b9ad25f272094cf963b13e7c3e"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/463da2b9ad25f272094cf963b13e7c3e"}],"title":"","html":"<html><head></head><body>This is an example of \"dare to dream\" ..\nThe hope is still alive, as&nbsp;long as they don't give up for all&nbsp;the&nbsp;investors out there including myself.&nbsp;[Observation]&nbsp;&nbsp;\nIt is a long journey - along the way giving myself pats for the good play&nbsp;<a href=\"https://ttm.financial/OPT/NVAX 20250228 7.0 PUT\">$NVAX 20250228 7.0 PUT$ </a><t-t type=\"img\" src=\"https://community-static.tradeup.com/news/463da2b9ad25f272094cf963b13e7c3e\"></t-t></body></html>","htmlText":"<html><head></head><body>This is an example of \"dare to dream\" ..\nThe hope is still alive, as&nbsp;long as they don't give up for all&nbsp;the&nbsp;investors out there including myself.&nbsp;[Observation]&nbsp;&nbsp;\nIt is a long journey - along the way giving myself pats for the good play&nbsp;<a href=\"https://ttm.financial/OPT/NVAX 20250228 7.0 PUT\">$NVAX 20250228 7.0 PUT$ </a><t-t type=\"img\" src=\"https://community-static.tradeup.com/news/463da2b9ad25f272094cf963b13e7c3e\"></t-t></body></html>","text":"This is an example of \"dare to dream\" .. The hope is still alive, as long as they don't give up for all the investors out there including myself. [Observation] It is a long journey - along the way giving myself pats for the good play $NVAX 20250228 7.0 PUT$","highlighted":1,"essential":1,"paper":1,"likeSize":13,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/408177892638840","repostId":2514804835,"repostType":2,"repost":{"id":"2514804835","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1740661356,"share":"https://ttm.financial/m/news/2514804835?lang=en_US&edition=fundamental","pubTime":"2025-02-27 21:02","market":"nz","language":"en","title":"Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=2514804835","media":"Reuters","summary":"Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines Feb 27 (Reuters) - Novavax's NVAX.O fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative ","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines</title></head><body>\nFeb 27 (Reuters) - Novavax's NVAX.O fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 vaccines, its only product on the market.The company has struggled to keep up with the pace of its rivals Moderna MRNA.O and Pfizer PFE.N, which make messenger RNA-based vaccines compared to its protein-based shot.Novavax reported quarterly sales of $49.8 million for COVID vaccines, down 80.2% from the year earlier.The U.S. company signed a licensing deal worth at least $1.2 billion with French drugmaker <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> SASY.PA in May to hand over the rights to sell its vaccines in several markets, including the United States and Europe.Maryland-based Novavax said it would continue to sell the shots in the U.S. during the first half of this year, as it transitions the market to <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> beginning with the 2025-2026 vaccination season.It is banking on revenue from its Sanofi deal and vaccines in development, including an experimental COVID-flu combination shot and for bird flu, which is in pre-clinical stage.Novavax said it was eligible to receive royalties in high teens to low twenties percent on Sanofi sales, along with $350 million in commercial launch payments associated with the COVID-flu combination products.The vaccine maker did not provide total revenue forecast for 2025, as it is reliant on Sanofi's sales estimates for certain revenue components.Shares of Novavax, along with other vaccine makers, took a hit this year after lawmakers advanced President Donald Trump's nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services towards confirmation.An environmental lawyer and a vaccine critic, Kennedy was confirmed to the role on February 13.Novavax's net loss was $81 million for the quarter ended December 31, compared with a net loss of $178.3 million a year ago.It ended 2024 with $938 million in cash and receivables, compared to $584 million as of December 31, 2023. (Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar) ((Christy.Santhosh@thomsonreuters.com))</body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax's quarterly loss shrinks as it ramps down spending on COVID vaccines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nReuters \n2025-02-27 21:02\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines</title></head><body>\nFeb 27 (Reuters) - Novavax's NVAX.O fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 vaccines, its only product on the market.The company has struggled to keep up with the pace of its rivals Moderna MRNA.O and Pfizer PFE.N, which make messenger RNA-based vaccines compared to its protein-based shot.Novavax reported quarterly sales of $49.8 million for COVID vaccines, down 80.2% from the year earlier.The U.S. company signed a licensing deal worth at least $1.2 billion with French drugmaker <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> SASY.PA in May to hand over the rights to sell its vaccines in several markets, including the United States and Europe.Maryland-based Novavax said it would continue to sell the shots in the U.S. during the first half of this year, as it transitions the market to <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> beginning with the 2025-2026 vaccination season.It is banking on revenue from its Sanofi deal and vaccines in development, including an experimental COVID-flu combination shot and for bird flu, which is in pre-clinical stage.Novavax said it was eligible to receive royalties in high teens to low twenties percent on Sanofi sales, along with $350 million in commercial launch payments associated with the COVID-flu combination products.The vaccine maker did not provide total revenue forecast for 2025, as it is reliant on Sanofi's sales estimates for certain revenue components.Shares of Novavax, along with other vaccine makers, took a hit this year after lawmakers advanced President Donald Trump's nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services towards confirmation.An environmental lawyer and a vaccine critic, Kennedy was confirmed to the role on February 13.Novavax's net loss was $81 million for the quarter ended December 31, compared with a net loss of $178.3 million a year ago.It ended 2024 with $938 million in cash and receivables, compared to $584 million as of December 31, 2023. (Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar) ((Christy.Santhosh@thomsonreuters.com))</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4139":"生物科技","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0122379950.USD":"贝莱德世界健康科学A2","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","SG9999001176.USD":"United Global Healthcare Acc USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4547":"WSB热门概念","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4592":"伊斯兰概念","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0234572021.USD":"高盛美国核心股票组合Acc","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4501":"段永平概念","BK4588":"碎股","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4548":"巴美列捷福持仓","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4007":"制药","BK4551":"寇图资本持仓","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4581":"高盛持仓","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL3N3PI113:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2514804835","content_text":"Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines\nFeb 27 (Reuters) - Novavax's NVAX.O fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 vaccines, its only product on the market.The company has struggled to keep up with the pace of its rivals Moderna MRNA.O and Pfizer PFE.N, which make messenger RNA-based vaccines compared to its protein-based shot.Novavax reported quarterly sales of $49.8 million for COVID vaccines, down 80.2% from the year earlier.The U.S. company signed a licensing deal worth at least $1.2 billion with French drugmaker Sanofi SASY.PA in May to hand over the rights to sell its vaccines in several markets, including the United States and Europe.Maryland-based Novavax said it would continue to sell the shots in the U.S. during the first half of this year, as it transitions the market to Sanofi beginning with the 2025-2026 vaccination season.It is banking on revenue from its Sanofi deal and vaccines in development, including an experimental COVID-flu combination shot and for bird flu, which is in pre-clinical stage.Novavax said it was eligible to receive royalties in high teens to low twenties percent on Sanofi sales, along with $350 million in commercial launch payments associated with the COVID-flu combination products.The vaccine maker did not provide total revenue forecast for 2025, as it is reliant on Sanofi's sales estimates for certain revenue components.Shares of Novavax, along with other vaccine makers, took a hit this year after lawmakers advanced President Donald Trump's nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services towards confirmation.An environmental lawyer and a vaccine critic, Kennedy was confirmed to the role on February 13.Novavax's net loss was $81 million for the quarter ended December 31, compared with a net loss of $178.3 million a year ago.It ended 2024 with $938 million in cash and receivables, compared to $584 million as of December 31, 2023. (Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar) ((Christy.Santhosh@thomsonreuters.com))","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":693,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["NVAX"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["晒单贴"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":true,"length":208,"optionInvolvedFlag":true,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":408723143852424,"commentId":"408723143852424","gmtCreate":1740802272418,"gmtModify":1740806529387,"authorId":10000000000010968,"author":{"id":10000000000010968,"idStr":"10000000000010968","authorId":10000000000010968,"name":"Tiger_CashBoostAccount","avatar":"https://community-static.tradeup.com/news/ae2d4002ef9664aba005cb3020f416f5","vip":2,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":408177892638840,"objectIdStr":"408177892638840","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":" Congratulations on your succeed trades. Your investment acumen is really showing. Keep leveraging your knowledge to find those hidden gems in the market. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🎉🤓\n Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here.\n Other helpful links:\n <ul style=\"\"><li><a href=\"https://www.itiger.com/sg/help/detail/06324754?_sasdk=fNDE0MTg2NzAwNTE0OTk2Mg\" title=\"How to open a CBA.\" class=\"\">How to open a CBA.</a>\n </li><li><a href=\"https://www.itiger.com/sg/help/detail/how-to-link-CDP?_sasdk=fNDE0MTg2NzAwNTE0OTk2Mg\" title=\"How to link your CDP account.\" class=\"\">How to link your CDP account.</a>\n </li><li><a href=\"https://www.itiger.com/sg/help/detail/contra-faq?_sasdk=fNDE0MTg2NzAwNTE0OTk2Mg\" title=\"Other FAQs on CBA.\" class=\"\">Other FAQs on CBA.</a>&nbsp;\n </li><li><a href=\"https://www.itiger.com/sg/invest/cash-boost\" title=\"Cash Boost Account Website.\" class=\"\">Cash Boost Account Website.</a>\n <img src=\"https://community-static.tradeup.com/news/9cacb64c02a7bc16143db1b24ccaf6e6\" tg-width=\"1080\" tg-height=\"1080\">\n </li></ul>","text":" Congratulations on your succeed trades. Your investment acumen is really showing. Keep leveraging your knowledge to find those hidden gems in the market. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🎉🤓\n Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here.\n Other helpful links:\n <ul style=\"\"><li><a href=\"https://www.itiger.com/sg/help/detail/06324754?_sasdk=fNDE0MTg2NzAwNTE0OTk2Mg\" title=\"How to open a CBA.\" class=\"\">How to open a CBA.</a>\n </li><li><a href=\"https://www.itiger.com/sg/help/detail/how-to-link-CDP?_sasdk=fNDE0MTg2NzAwNTE0OTk2Mg\" title=\"How to link your CDP account.\" class=\"\">How to link your CDP account.</a>\n </li><li><a href=\"https://www.itiger.com/sg/help/detail/contra-faq?_sasdk=fNDE0MTg2NzAwNTE0OTk2Mg\" title=\"Other FAQs on CBA.\" class=\"\">Other FAQs on CBA.</a>&nbsp;\n </li><li><a href=\"https://www.itiger.com/sg/invest/cash-boost\" title=\"Cash Boost Account Website.\" class=\"\">Cash Boost Account Website.</a>\n <img src=\"https://community-static.tradeup.com/news/9cacb64c02a7bc16143db1b24ccaf6e6\" tg-width=\"1080\" tg-height=\"1080\">\n </li></ul>","html":" Congratulations on your succeed trades. Your investment acumen is really showing. Keep leveraging your knowledge to find those hidden gems in the market. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🎉🤓\n Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here.\n Other helpful links:\n <ul style=\"\"><li><a href=\"https://www.itiger.com/sg/help/detail/06324754?_sasdk=fNDE0MTg2NzAwNTE0OTk2Mg\" title=\"How to open a CBA.\" class=\"\">How to open a CBA.</a>\n </li><li><a href=\"https://www.itiger.com/sg/help/detail/how-to-link-CDP?_sasdk=fNDE0MTg2NzAwNTE0OTk2Mg\" title=\"How to link your CDP account.\" class=\"\">How to link your CDP account.</a>\n </li><li><a href=\"https://www.itiger.com/sg/help/detail/contra-faq?_sasdk=fNDE0MTg2NzAwNTE0OTk2Mg\" title=\"Other FAQs on CBA.\" class=\"\">Other FAQs on CBA.</a>&nbsp;\n </li><li><a href=\"https://www.itiger.com/sg/invest/cash-boost\" title=\"Cash Boost Account Website.\" class=\"\">Cash Boost Account Website.</a>\n <img src=\"https://community-static.tradeup.com/news/9cacb64c02a7bc16143db1b24ccaf6e6\" tg-width=\"1080\" tg-height=\"1080\">\n </li></ul>","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0}],"hasMoreComment":true,"orderType":2}